BioCryst Pharmaceuticals
BCRX
7.22
-0.10
-1.37%
BioCryst Pharmaceuticals
US · BCRX
#2766 by market cap
Listed 1970
7.22
-0.10
-1.37%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM), BioMarin Pharmaceutical (BMRN) and BioCryst (BCRX)TipRanks · 2026/10/21
-
Company notice
BioCryst Pharmaceuticals | 8-K: BioCryst Reports Third Quarter 2026 Financial ResultsSEC · 2026/11/4
-
Rating change
Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $16Market Newswire · 2026/9/9
-
Company notice
BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securitiesSEC · 2026/9/3
-
Rating change
J.P. Morgan Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Raises Target Price to $13Market Newswire · 2026/9/30
-
Rating change
Wedbush Cuts Price Target on BioCryst Pharmaceuticals to $18 From $20, Keeps Outperform RatingMT Newswires · 2026/10/19
-
Company notice
BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securitiesSEC · 2026/9/3
-
Rating change
TD Cowen Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/10/21
-
BioCryst Pharmaceuticals' Q3 Net Income, Revenue Rise; Increases 2026 Revenue GuidanceMT Newswires · 2026/11/4
-
Company notice
BioCryst Pharmaceuticals | SCHEDULE 13G: OthersSEC · 2026/11/10
-
Rating change
RBC Capital Downgrades BioCryst Pharmaceuticals(BCRX.US) to Hold Rating, Cuts Target Price to $11Market Newswire · 2026/9/10
-
Company notice
BioCryst Pharmaceuticals | 10-Q: Q3 2026 Earnings ReportSEC · 2026/11/5
-
Rating change
Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $20Market Newswire · 2026/8/6
-
Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $17Market Newswire · 2026/11/5
-
Rating change
BioCryst Pharmaceuticals Is Maintained at Neutral by JP MorganDow Jones · 2026/10/1
-
Rating change
H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $32Market Newswire · 2026/8/7
-
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Maintains Target Price $11Market Newswire · 2026/11/5
-
Rating change
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $15Market Newswire · 2026/10/9
-
Wedbush Adjusts BioCryst Pharmaceuticals PT to $17 From $18, Maintains Outperform RatingMT Newswires · 2026/11/5
-
Rating change
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $13Market Newswire · 2026/8/6
-
Rating change
Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform RatingMT Newswires · 2026/8/6
-
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Maintains Target Price $11Market Newswire · 2026/10/9
-
Rating change
RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform RatingMT Newswires · 2026/8/6
-
Company notice
BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securitiesSEC · 2026/9/3
-
Company notice
BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securitiesSEC · 2026/9/3
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.
BioCryst Pharmaceuticals discussion 0 comments